OPDIVO (nivolumab) is now the first PD-1 inhibitor approved for a blood cancer, having been approved by the Australian Therapeutic Goods Administration (TGA) for use in the treatment of adult patients with relapsed or refractory classical Hodgkin Lymphoma (cHL) under specific circumstances.
The Bristol-Myers Squibb drug is now approved in Australia for six indications across four distinct tumour types, including a number of solid tumours including non-small cell lung cancer, melanoma and advanced renal cell cancer.
Visit tga.gov.au for details.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Jun 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Jun 17